Delgocitinib, a Janus kinase (JAK) inhibitor, has received U.S. patent protection for its use in treating certain inflammatory conditions. The patent covers the compound itself and its therapeutic applications.
What is Delgocitinib Used For?
Delgocitinib is developed for the treatment of atopic dermatitis, a type of eczema characterized by itchy, inflamed skin. It works by inhibiting specific enzymes in the body that are involved in the inflammatory pathways associated with the condition [1].
When Does Delgocitinib's Patent Protection End?
The patent protection for delgocitinib in the United States will expire at different times depending on the specific patent. Drug patent expiry dates are critical for understanding when generic versions of a drug may become available. Information on specific patent expiry dates for delgocitinib can be found on resources like DrugPatentWatch.com [2].
Who is Developing Delgocitinib?
Torii Pharmaceutical Co., Ltd. is the company that developed delgocitinib. AbbVie has an exclusive license from Torii for the global development and commercialization of delgocitinib, excluding Japan and Asia [1].
How Does Delgocitinib Work?
Delgocitinib is an inhibitor of the Janus kinase (JAK) family of enzymes. By inhibiting JAKs, it modulates the signaling pathways that lead to inflammation and immune responses, thereby reducing the symptoms of atopic dermatitis [1].
What are the Clinical Trial Results for Delgocitinib?
Clinical trials have demonstrated the efficacy of delgocitinib in improving the signs and symptoms of atopic dermatitis. Studies have shown significant reductions in itch and skin inflammation in patients treated with the drug [1].
Are There Any Other Treatments for Atopic Dermatitis?
Yes, several other treatments are available for atopic dermatitis, including topical corticosteroids, topical calcineurin inhibitors, systemic immunosuppressants, and other biologics. Delgocitinib offers a novel mechanism of action as an oral JAK inhibitor for this condition [1].
What are the Potential Side Effects of Delgocitinib?
As with many medications, delgocitinib may have side effects. Common side effects reported in clinical trials include upper respiratory tract infections, nasopharyngitis, and dermatitis acneiform [1]. More serious potential risks associated with JAK inhibitors may include serious infections, malignancy, major adverse cardiovascular events, and thrombosis.
Can Generic Versions of Delgocitinib Be Made?
Generic versions of delgocitinib can potentially be manufactured and marketed once the relevant U.S. patents expire and regulatory approval is obtained. The availability of generic competition typically lowers drug prices.
Sources:
1. AbbVie Inc. (n.d.). Delgocitinib. Retrieved from https://www.abbvie.com/our-science/pipeline/delgocitinib.html
2. DrugPatentWatch.com. (n.d.). Delgocitinib. Retrieved from https://drugpatentwatch.com/delgocitinib